Skip to main content
. 2020 May 18;12(5):1275. doi: 10.3390/cancers12051275

Table 6.

Association between selected plasma biomarkers and freedom of liver recurrence (FLR), disease-free survival (DFS) and overall survival (OS) in hepatocellular carcinoma patients outside Milan criteria who underwent surgical treatments. p-value from Wald test in a univariable Cox regression using log-transformed covariates.

Biomarkers/
Outcome
FLR DFS OS
HR (95% CI) (n) p-Value HR (95% CI) (n) p-Value HR (95% CI) (n) p-Value
LT
sVEGFR1 1.00 (0.54, 1.83) (17) 0.99 1.00 (0.68, 1.47) (17) 0.99 0.89 (0.57, 1.41) (17) 0.62
VEGF 2.00 (0.86, 4.65) (17) 0.11 1.53 (0.94, 2.49) (17) 0.085 1.34 (0.81, 2.23) (17) 0.25
VEGF-C 127.32 (0.20, 80,654) (17) 0.14 6.15 (1.60, 23.62) (17) 0.0082 5.41 (1.42, 20.64) (17) 0.014
IFN-γ 0.48 (0.15, 1.55) (17) 0.22 0.75 (0.37, 1.50) (17) 0.42 0.72 (0.34, 1.54) (17) 0.40
IL-6 1.07 (0.73, 1.59) (17) 0.72 1.14 (0.91, 1.44) (17) 0.26 1.06 (0.82,1.38) (17) 0.65
IL-8 1.31 (0.53, 3.24) (17) 0.57 1.36 (0.79, 2.34) (17) 0.26 1.30 (0.73, 2.29) (17) 0.37
IL-10 0.98 (0.61, 1.58) (17) 0.93 1.02 (0.77, 1.34) (17) 0.91 0.91 (0.64, 1.28) (17) 0.58
AFP 0.71 (0.21, 2.36) (13) 0.57 1.18 (0.57, 2.45) (13) 0.65 1.60 (0.67, 3.83) (13) 0.29
LR
sVEGFR1 0.80 (0.45, 1.42) (25) 0.44 1.06 (0.80, 1.39) (25) 0.69 1.43 (0.97, 2.10) (25) 0.073
VEGF 1.26 (0.74, 2.14) (25) 0.39 0.97 (0.71, 1.32) (25) 0.84 0.78 (0.52, 1.16) (25) 0.22
VEGF-C 1.03 (0.47, 2.27) (25) 0.94 1.03 (0.56, 1.90) (25) 0.92 1.19 (0.60, 2.35) (25) 0.61
IFN-γ 0.93 (0.52, 1.65) (25) 0.81 0.99 (0.61, 1.59) (25) 0.96 1.26 (0.73, 2.16) (25) 0.40
IL-6 1.33 (0.91, 1.94) (25) 0.15 1.23 (0.91, 1.66) (25) 0.17 1.13 (0.80, 1.58) (25) 0.49
IL-8 1.59 (0.93, 2.71) (25) 0.093 1.53 (0.99, 2.36) (25) 0.054 1.35 (0.78, 2.34) (25) 0.28
IL-10 1.09 (0.67, 1.78) (25) 0.79 1.38 (0.99, 1.92) (25) 0.060 1.56 (1.07, 2.27) (25) 0.021
AFP 0.82 (0.37, 1.82) (15) 0.63 1.05 (0.54, 2.06) (15) 0.88 1.24 (0.66, 2.32) (15) 0.50

AFP, alpha-fetoprotein; IFN, interferon; IL, interleukin; LR liver resection; LT, liver transplantation; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.